CL2014003572A1 - Compuestos derivados de aril-sultamo o una sal del mismo, como moduladores de la funcion del receptor de orfano rorc; composicion que los contiene; y su uso para el tratamiento o la profilaxis de la artritis. - Google Patents

Compuestos derivados de aril-sultamo o una sal del mismo, como moduladores de la funcion del receptor de orfano rorc; composicion que los contiene; y su uso para el tratamiento o la profilaxis de la artritis.

Info

Publication number: CL2014003572A1
Authority: CL; Chile
Prior art keywords: sultam; prophylaxis; modulators; arthritis; aryl
Prior art date: 2012-07-11

Application number

CL2014003572A

Other languages

English (en)

Inventor

Van Niel Monique Bodil

Benjamin Fauber

Simon Gaines

Alberto Gobbi

Olivier Rene

David Vesey

Stuart Ward

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-07-11

Filing date

2014-12-30

Publication date

2015-04-24

2014-12-30 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2015-04-24 Publication of CL2014003572A1 publication Critical patent/CL2014003572A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Thiazole And Isothizaole Compounds (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Plural Heterocyclic Compounds (AREA)

CL2014003572A 2012-07-11 2014-12-30 Compuestos derivados de aril-sultamo o una sal del mismo, como moduladores de la funcion del receptor de orfano rorc; composicion que los contiene; y su uso para el tratamiento o la profilaxis de la artritis. CL2014003572A1 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US201261670519P	2012-07-11	2012-07-11
US201361788430P	2013-03-15	2013-03-15
US201361837461P	2013-06-20	2013-06-20

Publications (1)

Publication Number	Publication Date
CL2014003572A1 true CL2014003572A1 (es)	2015-04-24

Family

ID=48782328

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014003572A CL2014003572A1 (es)	2012-07-11	2014-12-30	Compuestos derivados de aril-sultamo o una sal del mismo, como moduladores de la funcion del receptor de orfano rorc; composicion que los contiene; y su uso para el tratamiento o la profilaxis de la artritis.

Country Status (21)

Country	Link
US (1)	US9115101B2 (es)
EP (1)	EP2872504B1 (es)
JP (1)	JP6262228B2 (es)
KR (1)	KR20150029739A (es)
CN (2)	CN104470917B (es)
AR (1)	AR092348A1 (es)
AU (1)	AU2013288756A1 (es)
BR (1)	BR112015000581A2 (es)
CA (1)	CA2876449A1 (es)
CL (1)	CL2014003572A1 (es)
CO (1)	CO7141456A2 (es)
CR (1)	CR20140548A (es)
ES (1)	ES2612165T3 (es)
HK (1)	HK1244781A1 (es)
IL (1)	IL236293A0 (es)
MX (1)	MX2015000325A (es)
PE (1)	PE20151007A1 (es)
PH (1)	PH12014502788B1 (es)
SG (1)	SG11201408534VA (es)
TW (1)	TW201408652A (es)
WO (1)	WO2014009447A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5977837B2 (ja)	2011-12-21	2016-08-24	ノヴィラ・セラピューティクス・インコーポレイテッド	Ｂ型肝炎抗ウイルス剤
CN104583218B (zh)	2012-04-26	2018-04-24	百时美施贵宝公司	作为蛋白酶活化受体4(par4)抑制剂用于治疗血小板聚集的咪唑并噻二唑和咪唑并吡嗪的衍生物
TWI568722B (zh)	2012-06-15	2017-02-01	葛蘭馬克製藥公司	作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
NZ743463A (en)	2012-08-28	2019-09-27	Janssen Sciences Ireland Uc	Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
ES2649156T3 (es)	2013-01-14	2018-01-10	Incyte Holdings Corporation	Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
TW201932456A (zh)	2013-01-15	2019-08-16	美商英塞特控股公司	適用作pim激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物
MX366123B (es)	2013-02-28	2019-06-27	Janssen Sciences Ireland Uc	Sulfamoil-arilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis b.
EA027068B1 (ru)	2013-04-03	2017-06-30	Янссен Сайенсиз Айрлэнд Юси	Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
JO3603B1 (ar)	2013-05-17	2020-07-05	Janssen Sciences Ireland Uc	مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
CN105960400B (zh)	2013-05-17	2019-05-31	爱尔兰詹森科学公司	氨磺酰基噻吩酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
HK1220976A1 (zh) *	2013-06-21	2017-05-19	F. Hoffmann-La Roche Ag	作为rorc调节剂的芳基磺内酰胺衍生物
PL3024819T3 (pl)	2013-07-25	2018-08-31	Janssen Sciences Ireland Uc	Pochodne piroloamidowe podstawione glioksamidem i ich zastosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B
MX2016002367A (es)	2013-08-23	2016-10-28	Incyte Corp	Compuestos de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim.
EP3060547B1 (en)	2013-10-23	2017-10-11	Janssen Sciences Ireland UC	Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
TW201620884A (zh)	2014-01-10	2016-06-16	赫孚孟拉羅股份公司	作為ＲＯＲｃ調節劑之芳基磺內醯胺衍生物
WO2015104354A1 (en) *	2014-01-10	2015-07-16	F. Hoffmann-La Roche Ag	ARYL SULTAM DERIVATIVES AS RORc MODULATORS
US9169212B2 (en)	2014-01-16	2015-10-27	Novira Therapeutics, Inc.	Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en)	2014-01-16	2019-08-27	Novira Therapeutics, Inc.	Azepane derivatives and methods of treating hepatitis B infections
SG11201606080SA (en)	2014-02-03	2016-08-30	Vitae Pharmaceuticals Inc	Dihydropyrrolopyridine inhibitors of ror-gamma
US20150216938A1 (en)	2014-02-05	2015-08-06	Novira Therapeutics Inc.	Combination therapy for treatment of hbv infections
CN110483484A (zh)	2014-02-06	2019-11-22	爱尔兰詹森科学公司	氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
US9580418B2 (en)	2014-07-14	2017-02-28	Incyte Corporation	Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en)	2014-07-14	2016-01-21	Incyte Corporation	Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
CN104370755B (zh) *	2014-08-18	2017-04-12	江西隆莱生物制药有限公司	一种光学活性的3‑氨基丁醇和3‑氨基丁酸的制备方法
CN107074852B (zh)	2014-10-14	2019-08-16	生命医药有限责任公司	ROR-γ的二氢吡咯并吡啶抑制剂
US20170323472A1 (en) *	2014-10-26	2017-11-09	Galileo Group, Inc.	Methods and systems for surface informatics based detection with machine-to-machine networks and smartphones
US9663515B2 (en)	2014-11-05	2017-05-30	Vitae Pharmaceuticals, Inc.	Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en)	2014-11-05	2017-12-19	Vitae Pharmaceuticals, Inc.	Isoindoline inhibitors of ROR-gamma
JP2017537966A (ja) *	2014-12-17	2017-12-21	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ＲＯＲｃモジュレーターとしてのヘテロアリールアルキレンアリールスルタム誘導体
JP6854776B2 (ja)	2015-01-08	2021-04-07	インぺティスバイオサイエンスリミテッド	二環式化合物、その組成物および医薬用途
WO2016128908A1 (en)	2015-02-12	2016-08-18	Advinus Therapeutics Limited	Bicyclic compounds, compositions and medicinal applications thereof
CN107847762A (zh)	2015-03-19	2018-03-27	诺维拉治疗公司	氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法
US9540347B2 (en)	2015-05-29	2017-01-10	Incyte Corporation	Pyridineamine compounds useful as Pim kinase inhibitors
US10875876B2 (en)	2015-07-02	2020-12-29	Janssen Sciences Ireland Uc	Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
HK1250235A1 (zh) *	2015-07-08	2018-12-07	F. Hoffmann-La Roche Ag	作为rorc调节剂的芳基磺内酰胺衍生物
WO2017005668A1 (en) *	2015-07-08	2017-01-12	F. Hoffmann-La Roche Ag	ARYL SULTAM DERIVATIVES AS RORc MODULATORS
US10301261B2 (en)	2015-08-05	2019-05-28	Vitae Pharmaceuticals, Llc	Substituted indoles as modulators of ROR-gamma
TWI734699B (zh)	2015-09-09	2021-08-01	美商英塞特公司	Ｐｉｍ激酶抑制劑之鹽
HK1259410A1 (zh)	2015-09-29	2019-11-29	诺维拉治疗公司	乙型肝炎抗病毒剂的晶体形式
US9920032B2 (en)	2015-10-02	2018-03-20	Incyte Corporation	Heterocyclic compounds useful as pim kinase inhibitors
EP3377482B1 (en)	2015-11-20	2021-05-12	Vitae Pharmaceuticals, LLC	Modulators of ror-gamma
TWI757266B (zh)	2016-01-29	2022-03-11	美商維它藥物有限責任公司	ＲＯＲ－γ調節劑
CN109640980A (zh)	2016-04-15	2019-04-16	诺维拉治疗公司	包含壳体装配抑制剂的组合和方法
US9481674B1 (en)	2016-06-10	2016-11-01	Vitae Pharmaceuticals, Inc.	Dihydropyrrolopyridine inhibitors of ROR-gamma
BR112019008548A2 (pt) *	2016-10-27	2019-09-17	Escalier Biosciences Bv	moduladores ror-gama
CN106966912B (zh) *	2017-04-01	2019-07-02	沧州那瑞化学科技有限公司	(r)-3-氨基丁醇的制备方法
AU2018301335B2 (en)	2017-07-10	2022-09-15	Celgene Corporation	Antiproliferative compounds and methods of use thereof
MA49685A (fr)	2017-07-24	2021-04-14	Vitae Pharmaceuticals Llc	INHIBITEURS DE ROR gamma
WO2019018975A1 (en)	2017-07-24	2019-01-31	Vitae Pharmaceuticals, Inc.	INHIBITORS OF ROR GAMMA
WO2019022223A1 (ja) *	2017-07-28	2019-01-31	東レ株式会社	環状アミン誘導体及びその医薬用途
US10596161B2 (en)	2017-12-08	2020-03-24	Incyte Corporation	Low dose combination therapy for treatment of myeloproliferative neoplasms
US11242350B2 (en)	2018-03-12	2022-02-08	Escalier Biosciences B.V.	Spirocyclic ROR-gamma modulators
JP2021517563A (ja) *	2018-03-12	2021-07-26	エスカリアバイオサイエンシーズ，ビーブイ	二環式ＲＯＲγモジュレーター
CA3090125A1 (en)	2018-03-14	2019-09-19	Janssen Sciences Ireland Unlimited Company	Capsid assembly modulator dosing regimen
JP2022521081A (ja)	2019-02-22	2022-04-05	ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー	Ｈｂｖ感染若しくはｈｂｖ誘導性疾患の治療において有用なアミド誘導体
US11198699B2 (en)	2019-04-02	2021-12-14	Aligos Therapeutics, Inc.	Compounds targeting PRMT5
MA55879A (fr)	2019-05-06	2022-03-16	Janssen Sciences Ireland Unlimited Co	Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
CA3217423A1 (en)	2021-06-16	2022-12-22	Jeffrey M. Schkeryantz	Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101351209A (zh) *	2005-11-01	2009-01-21	转化技术制药公司	取代的酰胺的药学应用
JP2009514818A (ja) *	2005-11-01	2009-04-09	ハイポイントファーマシューティカルズ，リミティドライアビリティカンパニー	置換アミドの製薬学的用途
WO2011007819A1 (ja)	2009-07-17	2011-01-20	塩野義製薬株式会社	ラクタムまたはベンゼンスルホンアミド化合物を含有する医薬
EP2368886A1 (en) *	2010-03-01	2011-09-28	Phenex Pharmaceuticals AG	Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease
JP6063870B2 (ja)	2010-11-08	2017-01-18	ライセラ・コーポレイション	ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療
UY34765A (es)	2012-04-27	2013-11-29	Glaxo Group Ltd	Compuestos novedosos.

2013
- 2013-07-10 AR ARP130102439A patent/AR092348A1/es unknown
- 2013-07-10 TW TW102124802A patent/TW201408652A/zh unknown
- 2013-07-11 JP JP2015520984A patent/JP6262228B2/ja not_active Expired - Fee Related
- 2013-07-11 US US13/939,962 patent/US9115101B2/en not_active Expired - Fee Related
- 2013-07-11 BR BR112015000581A patent/BR112015000581A2/pt not_active IP Right Cessation
- 2013-07-11 EP EP13735278.7A patent/EP2872504B1/en not_active Not-in-force
- 2013-07-11 AU AU2013288756A patent/AU2013288756A1/en not_active Abandoned
- 2013-07-11 CA CA2876449A patent/CA2876449A1/en not_active Abandoned
- 2013-07-11 PE PE2015000022A patent/PE20151007A1/es not_active Application Discontinuation
- 2013-07-11 ES ES13735278.7T patent/ES2612165T3/es active Active
- 2013-07-11 WO PCT/EP2013/064637 patent/WO2014009447A1/en not_active Ceased
- 2013-07-11 CN CN201380036729.8A patent/CN104470917B/zh not_active Expired - Fee Related
- 2013-07-11 MX MX2015000325A patent/MX2015000325A/es unknown
- 2013-07-11 SG SG11201408534VA patent/SG11201408534VA/en unknown
- 2013-07-11 CN CN201710559460.1A patent/CN107235867A/zh active Pending
- 2013-07-11 KR KR20157003144A patent/KR20150029739A/ko not_active Withdrawn
2014
- 2014-11-28 CO CO14262762A patent/CO7141456A2/es unknown
- 2014-12-01 CR CR20140548A patent/CR20140548A/es not_active Application Discontinuation
- 2014-12-15 IL IL236293A patent/IL236293A0/en unknown
- 2014-12-15 PH PH12014502788A patent/PH12014502788B1/en unknown
- 2014-12-30 CL CL2014003572A patent/CL2014003572A1/es unknown
2018
- 2018-03-23 HK HK18104078.7A patent/HK1244781A1/zh unknown

Also Published As

Publication number	Publication date
CA2876449A1 (en)	2014-01-16
WO2014009447A1 (en)	2014-01-16
JP2015522057A (ja)	2015-08-03
US9115101B2 (en)	2015-08-25
CO7141456A2 (es)	2014-12-12
AU2013288756A1 (en)	2015-01-15
MX2015000325A (es)	2015-04-14
CN107235867A (zh)	2017-10-10
US20140031330A1 (en)	2014-01-30
ES2612165T3 (es)	2017-05-12
SG11201408534VA (en)	2015-02-27
PH12014502788A1 (en)	2015-02-09
TW201408652A (zh)	2014-03-01
CR20140548A (es)	2015-02-12
IL236293A0 (en)	2015-02-26
PH12014502788B1 (en)	2015-02-09
CN104470917A (zh)	2015-03-25
EP2872504A1 (en)	2015-05-20
EP2872504B1 (en)	2016-11-16
PE20151007A1 (es)	2015-06-29
BR112015000581A2 (pt)	2017-06-27
HK1208679A1 (en)	2016-03-11
HK1244781A1 (zh)	2018-08-17
CN104470917B (zh)	2017-08-04
JP6262228B2 (ja)	2018-01-17
KR20150029739A (ko)	2015-03-18
AR092348A1 (es)	2015-04-15

Publication	Publication Date	Title
CL2014003572A1 (es)	2015-04-24	Compuestos derivados de aril-sultamo o una sal del mismo, como moduladores de la funcion del receptor de orfano rorc; composicion que los contiene; y su uso para el tratamiento o la profilaxis de la artritis.
BR112015001596A2 (pt)	2017-08-01	composição para o tratamento de hiperlipidemia que compreende oxintomodulina.
CL2014001855A1 (es)	2014-12-05	Compuestos derivados de imidazopirrolidinona o sus sales, formas cristalinas; composicion farmaceutica que los comprende; y su uso para el tratamiento de un trastorno o enfermedad mediada por la actividad de mdm2 y/o mdm4 tales como enfermedades proliferativas, especialmente cancer.
CL2016001911A1 (es)	2017-02-10	Compuesto heterocíclico fusionado
MX377534B (es)	2025-03-10	Compuestos para usarse en el tratamiento de hiperinsulinemia.
CL2014002915A1 (es)	2015-02-13	Compuestos derivados de imidazotiadiazol e imidazopirazina, como inhibidores del receptor activado de proteasa 4 (par4); composicion farmaceutica que los comprende; y su uso para inhibir o prevenir la agregacion plaquetaria y por lo tanto utiles en el tratamiento de un trastorno tromboembolico o para la profilaxis primaria o secundaria de un trastorno tromboembolico.
CL2016001079A1 (es)	2017-01-20	Nuevos compuestos para el combate de artrópodos.
CL2014001065A1 (es)	2014-07-25	Compuestos derivados de piridopirazinas; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de un estado patologico o afeccion mediada por una fgfr cinasa tal como cancer.
UY34832A (es)	2013-12-31	TIAZOLES SUSTITUIDOS POR CARBOXAMIDA O SULFONAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUÉRFANO RORy (lambda)
UY36445A (es)	2016-07-29	Compuestos moduladores de fxr (nr1h4 que contiene grupos hidroxi)
CL2014001793A1 (es)	2014-11-07	Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2014002873A1 (es)	2015-04-24	Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2016003246A1 (es)	2017-07-14	Compuestos de dihidroisoquinolinona sustituida
MX395458B (es)	2025-03-25	Metodos novedosos
DK3229810T3 (da)	2020-08-17	Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler
CL2014002756A1 (es)	2015-06-12	Compuestos derivados de 1,4-benzotiazepina; composición farmacéutica que lo comprende; uso para tratar afecciones relacionadas con función anormal de receptores de rianodina; y método de preparación del compuesto.
DK3131902T3 (da)	2019-09-02	Forbindelser som ROR-gamma-modulatorer
DK3294713T5 (da)	2021-05-31	Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer
ES2897914T8 (es)	2022-03-17	Compuestos que contienen nitrógeno, adecuados para el uso en la producción de poliuretanos
CL2015001014A1 (es)	2015-08-28	Composicion de silicato de zirconio microporoso, util para el tratamiento de la hipercalemia
CL2015001279A1 (es)	2015-06-26	Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
CL2015000976A1 (es)	2015-12-18	Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
BR112012031239A2 (pt)	2016-10-04	“fechamento de segurança removível acionado por máquina para um membro tubular”
CL2016001210A1 (es)	2016-12-16	Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
CL2016001095A1 (es)	2016-11-11	Silicato de zirconio microporoso para el tratamiento de hipercalemia.